Cardiff University

The urine-based test, which uses a novel cancer biomarker to detect new and recurrent bladder cancer, has both the CE mark and FDA breakthrough device designation.

The collaborators aim to show that Cytox' VariaTect SNP profiling array and an associated algorithm can effectively predict the presence of Alzheimer's pathology.

The developers maintain that the new assay would address an unmet market need for a DMD screening test.